RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:397735

Autosomal dominant Charcot-Marie-Tooth disease type 2U

low confidenceDisorder

Also known as: Autosomal dominant Charcot-Marie-Tooth disease type 2 due to MARS mutation · CMT2U

Publications

527

Trials

0

Interventional, condition-specific

Researchers

186

Distinct authors in sample

Gene link

MARS1

Strong

Readiness

4/6

Stages with a signal

Clinical definition (Orphanet)

A subtype of Charcot-Marie-Tooth disease type 2, characterized by late adult-onset (50-60 years of age) of slowly , axonal, peripheral sensorimotor resulting in distal upper limb and proximal and distal lower limb muscle weakness and atrophy, in conjunction with distal, panmodal sensory impairment in upper and lower limbs. Tendon reflexes are reduced and nerve conduction velocities range from reduced to absent. Neuropathic pain has also been associated.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (4)

Charcot-Marie-Tooth disease type 2 caused by mutation in MARS · MARS Charcot-Marie-Tooth disease type 2 · autosomal dominant Charcot-Marie-Tooth disease type 2 due to MARS mutation · autosomal dominant Charcot-Marie-Tooth disease type 2U

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

4/6 stages with a signal

No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.

  1. Gene identifiedPresent

    Strong — MARS1

  2. LiteraturePresent

    527 matched papers (480 in last 10 years) Source

  3. Phenotype characterisedPresent

    10 HPO annotations (e.g. Areflexia; Peripheral axonal neuropathy; Hand muscle weakness) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialPartial

    None under the specific name; 42 for broader category Charcot-Marie-Tooth disease

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (MARS1).

GenCC classification: Strong.

Phenotypes (Monarch / HPO)

10

Associated phenotypes · MONDO:0014566

  • Areflexia
  • Peripheral axonal neuropathy
  • Hand muscle weakness
  • Steppage gait
  • Distal muscle weakness

Showing 5 of 10 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-27

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

527

527 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

527 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

480 in the last 10 years · low confidence

Phrase hits: 35 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

186

Distinct author names in 35 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Antonellis A4 papers · 2019

    Department of Human Genetics, University of Michigan Medical School, Ann Arbor, MI, United States; Cellular and Molecular Biology Program, University of Michigan Medical School, Ann Arbor, MI, United States. Electronic address: antonell@umich.edu.

    Papers in Europe PMC
  2. 02
    Meyer-Schuman R3 papers · 2019

    Department of Human Genetics, University of Michigan Medical School, Ann Arbor, MI 48109, USA.

    Papers in Europe PMC
  3. 03
    Chung KW2 papers · 2020

    Department of Biological Sciences, Kongju National University, Gongju 32588, Korea.

    Papers in Europe PMC
  4. 04
    Adir V1 paper · 2018

    The Human Genetics institute, Carmel Medical Center, Haifa, Israel.

    Papers in Europe PMC
  5. 05
    Bai J1 paper · 2023

    Department of Neurosurgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, People's Republic of China.

    Papers in Europe PMC
  6. 06
    Beg AA1 paper · 2017

    Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, United States.

    Papers in Europe PMC
  7. 07
    Bindu PS1 paper · 2022

    Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, Karnataka, India.

    Papers in Europe PMC
  8. 08
    Bird TD1 paper · 1993

    Seattle VA Medical Center, Departments of Neurology and Medicine, University of Washington, Seattle, Washington

    Papers in Europe PMC
  9. 09
    Boczonadi V1 paper · 2018

    Wellcome Centre for Mitochondrial Research, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.

    Papers in Europe PMC
  10. 10
    Boycott KM1 paper · 2019

    Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, ON, Canada.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 42 trials are registered for Charcot-Marie-Tooth disease, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 9 September 2026 · last trial check 9 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

low confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

42 interventional trials matched Charcot-Marie-Tooth disease, the broader category — listed below. Those studies are not counted in the condition-specific total.

Broader category: Charcot-Marie-Tooth disease

42

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-27

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Autosomal dominant Charcot-Marie-Tooth disease type 2U — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("Autosomal dominant Charcot-Marie-Tooth disease type 2U" OR "Autosomal dominant Charcot-Marie-Tooth disease type 2 due to MARS mutation" OR "CMT2U" OR "Charcot-Marie-Tooth disease type 2 caused by mutation in MARS" OR "MARS Charcot-Marie-Tooth disease type 2") OR ("MARS1" OR "MARS1 syndrome" OR "MARS1-related")

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Autosomal dominant Charcot-Marie-Tooth disease type 2U" OR "Autosomal dominant Charcot-Marie-Tooth disease type 2 due to MARS mutation" OR "CMT2U" OR "Charcot-Marie-Tooth disease type 2 caused by mutation in MARS" OR "MARS Charcot-Marie-Tooth disease type 2"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"Charcot-Marie-Tooth disease"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (527) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity

Ingested 2026-07-26T01:38:56.650Z